Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources
- PMID: 2177777
- DOI: 10.1002/jmv.1890320205
Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources
Abstract
The excretion of virus by 30 children was followed over a period of 28 days after their first vaccination with live oral poliovaccine. The type 1 and type 2 strains were isolated at similar high frequencies throughout this period, while the type 3 strain was not excreted by most children after day 2 post vaccination. Mutations in the 5' non-coding region associated with the attenuated phenotype reverted most rapidly for type 3 and least rapidly for type 1. The data are consistent with different degrees of selection against the attenuating mutations in the three serotypes in the gut, but imply that reversion is required for prolonged excretion. The findings also provide a possible explanation for the reported distribution of the rarely occurring vaccine associated cases between recipients and contacts for the three serotypes. A statistically significant difference was not observed between vaccine from the two main suppliers to the UK market.
Similar articles
-
Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.J Gen Virol. 1986 Apr;67 ( Pt 4):693-706. doi: 10.1099/0022-1317-67-4-693. J Gen Virol. 1986. PMID: 2420925
-
Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children.J Med Virol. 1987 Nov;23(3):249-56. doi: 10.1002/jmv.1890230307. J Med Virol. 1987. PMID: 2828521
-
Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.J Med Virol. 2005 Jan;75(1):153-60. doi: 10.1002/jmv.20250. J Med Virol. 2005. PMID: 15543587
-
Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.Acta Virol. 1996 Jun;40(3):157-70. Acta Virol. 1996. PMID: 8891097 Review.
-
[Eradication of poliomyelitis and emergence of pathogenic vaccine-derived polioviruses: from Madagascar to Cameroon].Med Sci (Paris). 2013 Nov;29(11):1034-41. doi: 10.1051/medsci/20132911021. Epub 2013 Nov 20. Med Sci (Paris). 2013. PMID: 24280508 Review. French.
Cited by
-
Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine.Vaccines (Basel). 2022 Aug 25;10(9):1394. doi: 10.3390/vaccines10091394. Vaccines (Basel). 2022. PMID: 36146473 Free PMC article.
-
Animal and human RNA viruses: genetic variability and ability to overcome vaccines.Arch Microbiol. 2021 Mar;203(2):443-464. doi: 10.1007/s00203-020-02040-5. Epub 2020 Sep 28. Arch Microbiol. 2021. PMID: 32989475 Free PMC article. Review.
-
Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.J Virol. 1995 Dec;69(12):7601-5. doi: 10.1128/JVI.69.12.7601-7605.1995. J Virol. 1995. PMID: 7494267 Free PMC article.
-
Neurovirulence of type 1 polioviruses isolated from sewage in Japan.Appl Environ Microbiol. 2002 Jan;68(1):138-42. doi: 10.1128/AEM.68.1.138-142.2002. Appl Environ Microbiol. 2002. PMID: 11772619 Free PMC article.
-
Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.J Virol. 2000 Apr;74(7):3001-10. doi: 10.1128/jvi.74.7.3001-3010.2000. J Virol. 2000. PMID: 10708414 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical